MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$3,544K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Other current assets
Depreciation expense
Stock-based compensation
Negative Cash Flow Breakdown
Net loss
Accrued expenses
Accounts payable
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-2,728
-2,666
-3,261
-7,451
Stock-based compensation
2
1
2
138
Stock option cancellations
-
0
0
3,732
Issuance of common stock for equity line of credit commitment fee
-
0
0
267
Depreciation expense
3
3
4
2
Gross proceeds from warrant inducement
-
0
2,546
-
Issuance of common stock, net of discount for lack of marketability
-
0
0
0
Direct transaction costs for warrant inducement
-
0
291
-
Other current assets
-73
320
-159
27
Gross proceeds from issuance of pre-funded warrants
-
-
4,995
-
Gross proceeds from issuance and exercises of pre-funded warrants
-
5,000
-
-
Accounts payable
-329
22
-164
26
Direct financing costs for issuance of pre-funded warrants
-
35
450
-
Accrued expenses
-565
68
291
-504
Gross proceeds from issuance of common stock, pre-funded and common warrants
-
0
0
-
Net cash used in operating activities
-3,544
-2,892
-2,969
-3,817
Direct transaction costs for issuance of common stock, pre-funded and common warrants
-
0
-
-
Purchase of property and equipment
-
3
7
0
Payment of issuance costs for registration statement
-
0
-64
-
Net cash used in investing activities
-
-3
-7
0
Gross proceeds from exercise of warrants
-
-5
-2,541
2,546
Gross proceeds from issuance of common stock
-
0
909
2,622
Issuance of common stock
0
0
-
-
Direct transaction costs for warrant inducement
-
-
-
291
Direct financing costs from issuance of common stock
0
0
26
115
Net cash provided by financing activities
0
-35
5,433
2,705
Net decrease in cash and cash equivalents
-3,544
-2,930
2,457
-1,112
Cash and cash equivalents, at beginning of period
7,004
7,477
7,477
9,136
Cash and cash equivalents, at end of period
3,460
7,004
9,934
7,477
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net decrease in cash
and cash...
-$3,544K
(-547.90%↓ Y/Y)
Other current assets
-$73K
(13.10%↑ Y/Y)
Depreciation expense
$3K
(0.00%↑ Y/Y)
Stock-based compensation
$2K
(-99.48%↓ Y/Y)
Net cash used in
operating activities
-$3,544K
(-36.10%↓ Y/Y)
Canceled cashflow
$78K
Net loss
-$2,728K
(18.25%↑ Y/Y)
Accrued expenses
-$565K
(-578.81%↓ Y/Y)
Accounts payable
-$329K
(-335.00%↓ Y/Y)
Buy us a coffee
Autonomix Medical, Inc. (AMIX)
Autonomix Medical, Inc. (AMIX)